Promising combo for aggressive breast cancer fails to finish
NCT ID NCT03838367
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tested a drug called leronlimab combined with chemotherapy (carboplatin) in people with a specific type of advanced triple-negative breast cancer that has spread. Only 10 patients were enrolled before the trial was stopped early. The goal was to find a safe dose and see if the combination could slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD07 Investigational Site
Chicago, Illinois, 60611, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.